Satellos Bioscience Return on Equity (ROE) Growth & History (MSLE)
Satellos Bioscience's return on equity was −66.37% for fiscal 2025.
View full Satellos Bioscience company overviewSatellos Bioscience annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −66.37% | −13.41 pp |
| 2024 | 2024-12-31 | −52.96% | — |
Satellos Bioscience quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −17.95% | −3.93 pp |
| Q1 2026 | 2026-03-31 | −19.84% | −6.02 pp |
| Q4 2025 | 2025-12-31 | −23.64% | — |
| Q3 2025 | 2025-09-30 | −16.09% | — |
| Q2 2025 | 2025-06-30 | −14.02% | — |
| Q1 2025 | 2025-03-31 | −13.83% | — |
Satellos Bioscience return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Satellos Bioscience's return on equity decreased from −52.96% to −66.37%, a change of −13.41 percentage points. The latest reported quarter, Q2 2026, shows −17.95%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Satellos Bioscience source filings ↗